

FORM 7

MONTHLY PROGRESS REPORT

For AUGUST, 2015

Name of CNSX Issuer: Network Life Sciences Inc. (formerly Network Oncology Inc.)
(the "Company").

Trading Symbol: NOI

Number of Outstanding Listed Securities: 26,836,392 common shares and 4,166,666 share purchase warrants as at August 31, 2015.

Date: September 3, 2015

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer did not have any cash flow from operations.

2. Provide a general overview and discussion of the activities of management.

On August 17, 2015 the Company announced it had appointed Dr. Alexander P. Goumeniouk to the Board of Directors. Dr. Goumeniouk has been a member of the department of Anesthesiology, Pharmacology and Therapeutics at the University of British Columbia (UBC) in the Faculty of Medicine for 25 years. He currently holds the rank of Professor Emeritus. Dr. Goumeniouk has a degree from Queen's University as well as his B.Sc. and M.D. from UBC. He has also trained at the University of Western Ontario (Internal medicine), Harvard (mini-fellowship in transcranial magnetic stimulation) and is board certified in psychiatry from his residency at UBC.

Dr. Goumeniouk consults internationally to pharmaceutical companies and also is the patent holder of a rapid, point-of-care diagnostic test (US 6,046,019).

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

This item is not applicable to the Company during the month of August 2015

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

This item is not applicable to the Company.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The Issuer did not enter into any new business relationship in August 2015.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

During the month of August 2015 there were no expiries or termination of any contracts or agreements between the Company, its affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

This item is not applicable to the Company during the month of August 2015

8. Describe the acquisition of new customers or loss of customers.

This item is not applicable to the Company during the month of August 2015.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

The Company possesses a well-diversified portfolio of drug assets in the oncological generics field and plans to use its technical and commercial expertise to develop markets to sell their portfolio of value-added products and services throughout Europe while offering significant cost savings to patients and payers.

Network Life Sciences Inc. has acquired in June, 2015 an exclusive worldwide license for a proprietary rapid point-of-care test for the detection of the Ebola virus in humans.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

This item is not applicable to the Company.

11. Report on any labour disputes and resolutions of those disputes if applicable.

This item is not applicable to the Company.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The Company was not party to any legal proceedings.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

As of August 31, 2015, the Company has an approximate aggregate amount of \$103,725 in demand loans inclusive of accrued interest at 8% per annum.

14. Provide details of any securities issued and options or warrants granted.

On August 17, 2015 the Company announced a non-brokered private placement (the "Private Placement") of up to 5,000,000 units of the Corporation (the "Units") at a price of CDN\$0.20 per Unit for aggregate gross proceeds of up to \$1,000,000. Each Unit will consist of one common share of the Corporation (a "Unit Share") and one-half common share purchase warrant. Each whole Warrant (a "Warrant") will entitle the holder to purchase one common share ("a "Warrant Share") at a price of \$0.50 per Warrant Share at any time until the close of business on the day which is 12 months from the date of issue of the Warrant (the "Expiry Time").

During the month of August 2015 the Company issued 2,100,000 incentive stock options at an exercise price of \$0.25 to certain directors, officers, employees, and consultants of the Company.

15. Provide details of any loans to or by Related Persons.

The Company has no loans to any related parties.

16. Provide details of any changes in directors, officers or committee members.

During the month of August 2015 the Company appointed a new Director as noted in #2 above.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Company are detailed in Item 17 of the Company's Form 2A Listing Statement under "Risk Factors".

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. To the best of the undersigned's knowledge and belief, as of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CNSX that, to the best of the undersigned's knowledge and belief, the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
4. To the best of the undersigned's knowledge and belief, all of the information in this Form 7 Monthly Progress Report is true.

Dated Sept 3, 2015.

Bill Thomas
Name of Director or Senior Officer

Bill Thomas
Signature
CFO & Director
Official Capacity

<i>Issuer Details</i>	For Month End	Date of Report YY/MM/DD
Name of Issuer		
Network Oncology Inc.	August 2015	15/09/03
Issuer Address		
815 Hornby Street, Suite 605		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Vancouver, B.C. V6Z 2E6		(604) 649-5245
Contact Name	Contact Position	Contact Telephone
Bill Thomas	CFO	(604) 649-5245
Contact Email Address	Web Site Address	
info@networkoncology.com	www.networkoncology.com	